# US 2025/0375464 A1 · Formulations for modulating myc expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375464 A1
- Document ID: US20250375464A1
- Status: Published application
- Kind: A1
- Application number: 18/877,408
- Filed: 2023-06-22
- Published: 2025-12-11
- Earliest claimed: 2022-06-22
- Assignees: Flagship Pioneering Innovations V, Inc.; Acuitas Therapeutics, Inc.
- Applicants: Flagship Pioneering Innovations V, Inc.; Acuitas Therapeutics, Inc.
- Inventors: Abigail Elizabeth Witt; Jeremiah Dale Farelli; Adam Walter Scheidegger; William Thomas Senapedis; Jodi Michelle Kennedy; Houda Belaghzal; Steven M. Ansell; Xinyao Du; Paulo Jia Ching Lin; Ying K. Tam
- Web page: https://patentgrep.com/patent/US20250375464A1

## CPC

- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 35/00: Antineoplastic agents
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates to compositions and methods for reducing expression of MYC gene in a cell. In some embodiments, an expression repressor comprises a targeting moiety that binds a MYC promoter, anchor sequence, or super-enhancer. In some embodiments, the expression repressor comprises an effector moiety that represses transcription or methylates DNA. Systems comprising two expression repressors are also disclosed. The compositions can be used, for example, to treat cancers such as HCC.

## Claims

### Claim 1

A composition comprising:
(1) a nucleic acid (e.g., RNA, e.g., mRNA) encoding an expression repressor, wherein the expression repressor comprises:
(a) a targeting moiety that binds to a MYC promoter, and
(b) optionally, an effector moiety,
wherein the expression repressor is capable of decreasing expression of MYC; and
(2) a formulation comprising one or both of:
(i) a first compound having a general structure of formula (I)
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein L1 and L2 are each independently —O(C═O)—, —(C═O)O—, —C(═O)—, —O—, —S(O)x—, —S—S—, —C(═O)S—, SC(═O)—, —NRC(═O)—, —C(═O)NRa—, —NRaC(═O)NRa—, —OC(═O)NRa—, —NRaC(═O)O—, or a direct bond;
G1 and G2 are each independently unsubstituted C1-C12 alkylene or C2-C12 alkenylene;
G3 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene;
Ra is H or C1-C12 alkyl;
R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
R3 is H, OR5, CN, —C(═O)OR4, —OC(═O)R4, —NR11R12, or —NR5C(═O)R4;
R4 is C1-C12 alkyl;
R5 is H or C1-C6 alkyl;
R11 and R12 are each independently C1-C12 alkyl or -G4-OR5, or R11 and R12, together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring;
G4 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene; and
x is 0, 1 or 2; and
(ii) a second compound having a general structure of formula (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein R6 and R7 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
y has mean value ranging from 30 to 60.

### Claim 2 (depends on 1)

The composition of claim 1, which comprises (i).

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, which comprises (ii).

### Claim 4 (depends on 1, 2, 3)

The composition of any of claims 1-3, which comprises:
(iii) a neutral lipid, such as phosphatidylcholine, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The composition of any of claims 1-4, which comprises:
(iv) a sterol, such as cholesterol or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 6

A composition comprising:
(1) a nucleic acid (e.g., RNA, e.g., mRNA) encoding an expression repressor, wherein the expression repressor comprises:
(a) a first targeting moiety that binds a genomic locus comprising at least 16, 17, 18, 19, or 20 nucleotides of the sequence of any of SEQ ID NOs: 83, 2, 3, 75-86, 97-107, 109, 110, 190-192, or 199-202, and
(b) optionally, a first effector moiety,
wherein the expression repressor is capable of decreasing expression of MYC; and
(2) a formulation comprising one or both of:
(i) a first compound having a general structure of formula (I)
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein L1 and L2 are each independently —O(C═O)—, —(C═O)O—, —C(═O)—, —O—, —S(O)x—, —S—S—, —C(═O)S—, SC(═O)—, —NRaC(═O)—, —C(═O)NRa—, —NRaC(═O)NRa—, —OC(═O)NRa—, —NRaC(═O)O—, or a direct bond;
G1 and G2 are each independently unsubstituted C1-C12 alkylene or C2-C12 alkenylene;
G3 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene;
Ra is H or C1-C12 alkyl;
R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
R3 is H, OR5, CN, —C(═O)OR4, —OC(═O)R4, —NR11R12, or —NR5C(═O)R4;
R4 is C1-C12 alkyl;
R5 is H or C1-C6 alkyl;
R11 and R12 are each independently C1-C12 alkyl or -G4-OR5, or R11 and R12, together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring;
G4 is C1-C24 alkylene, C2-C24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene; and
x is 0, 1 or 2; and
(ii) a second compound having a general structure of formula (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein R6 and R7 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
y has mean value ranging from 30 to 60.

### Claim 7 (depends on 6)

The composition of claim 6, which comprises (i).

### Claim 8 (depends on 6, 7)

The composition of claim 6 or 7, which comprises (ii).

### Claim 9 (depends on 6, 7, 8)

The composition of any of claims 6-8, which comprises:
(iii) a neutral lipid, such as phosphatidylcholine, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 10 (depends on 6, 7, 8, 9)

The composition of any of claims 6-9, which comprises:
(iv) a sterol, such as cholesterol, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 11

The composition of any of the preceding claims, wherein the first compound has a general structure of formula (III):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein L1 and L2 are each independently —(C═O)O— or —O(C═O)—;
R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
R3 occurs once and is H, OR5, CN, —C(═O)OR4, —OC(═O)R4 or —NR5C(═O)R4;
R4 is C1-C12 alkyl;
R5 is H or C1-C6 alkyl;
R occurs n times and is, at each occurrence, independently H, OH or C1-C24 alkyl;
n is an integer ranging from 1 to 15;
and m and 1 are each independently integers ranging from 1 to 12.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any of claims 1-11, wherein the first compound has a general structure of formula (IV):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein R1 and R2 are each independently C6-C24 alkyl or C6-C24 alkenyl;
R3 is H, OR5, CN, —C(═O)OR4, —OC(═O)R4 or —NR5C(═O)R4;
R4 is C1-C12 alkyl;
R5 is H or C1-C6 alkyl;
R8 is H, OH or C1-C24 alkyl;
n is an integer ranging from 1 to 15; and
m and 1 are each independently integers ranging from 1 to 12.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The composition of any of claims 1-12, wherein the first compound comprises any of the following:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any of claims 1-13, wherein the first compound comprises:

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any of claims 1-13, wherein the first compound comprises:

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The composition of any of claims 1-13, wherein the first compound comprises
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any of claims 1-16, wherein the second compound comprises any of the following:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein n has mean value ranging from 30 to 60.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The composition of any of claims 1-17, wherein the second compound comprises
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The composition of any of claims 1-18, wherein:
the first compound comprises:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof; and
the second compound comprises:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any of claims 1-19, wherein the phosphatidylcholine comprises Distearoylphosphatidylcholine (DSPC) (Formula V):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any of claims 1-20, wherein the sterol comprises cholesterol (Formula VI):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of claims 1-21, the composition comprising:
the first compound comprising:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof; and
the second compound comprising:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof;
the neutral lipid (e.g., phosphatidylcholine) comprising Distearoylphosphatidylcholine (DSPC) (Formula V):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof; and
cholesterol (Formula VI):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any of claims 1-22, wherein the molar ratio of (i):(ii):(iii):(iv) is any of the following:
(38-57):(2-3):(8-12):(32-48);
(42.75-52.25):(2.25-2.75):(9-11):(36-44);
(45.125-49.875):(2.375-2.625):(9.5-10.5):(38-42); or
47.5:2.5:10:40.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any of claims 1-22, wherein the molar ratio of (i):(ii):(iii):(iv) is about 47.5:2.5:10:40.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any of claims 1-24, wherein one or more of:
the first compound comprises about 47.5 molar % of the sum of (i), (ii), (iii), and (iv);
the second compound comprises about 2.5 molar % of the sum of (i), (ii), (iii), and (iv);
the phosphatidylcholine or pharmaceutically acceptable salt, tautomer or stereoisomer thereof comprises about 10 molar % of the sum of (i), (ii), (iii), and (iv); and
the sterol or pharmaceutically acceptable salt, tautomer or stereoisomer thereof comprises about 40 molar % of the sum of (i), (ii), (iii), and (iv),
wherein the first compound, the second compound, the phosphatidylcholine or pharmaceutically acceptable salt, tautomer or stereoisomer thereof, and the sterol or pharmaceutically acceptable salt, tautomer or stereoisomer thereof comprise 100 molar % of the sum of (i), (ii), (iii), and (iv).

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The composition of any of claims 1-25, wherein (1) and (2) form lipid nanoparticles (LNPs), wherein optionally the nucleic acid encapsulated within the LNPs.

### Claim 27

The composition of any of the preceding claims, wherein the formulation forms a lipid nanoparticle (LNP), and the nucleic acid is encapsulated within the LNP.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The composition of any of claims 1-27, wherein the nucleic acid comprises an RNA, e.g., an mRNA.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any of claims 1-28, which has an N:P ratio of between 3 and 22, between 4 and 12, between 4 and 8, between 5 and 9, between 5 and 7, between 5.5 and 6.5, between 6 and 9, between 7 and 9, between 6 and 8, about 5, about 6, about 7, or about 8.

### Claim 30 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The composition of any of claims 6-29, wherein:
the first targeting moiety binds a genomic locus comprising at least 16, 17, 18, 19, or 20 nucleotides of the sequence of SEQ ID NO: 83, and
the expression repressor comprises the first effector moiety, wherein the first effector moiety comprises a DNA methyltransferase.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the first targeting moiety comprises a zinc finger domain.

### Claim 32 (depends on 30, 31)

The composition of claim 30 or 31, wherein the first targeting moiety comprises an amino acid sequence according to SEQ ID NO: 13 or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 33 (depends on 30, 31, 32)

The composition of any of claims 30-32, wherein the first effector moiety comprises MQ1 or a functional variant or fragment thereof.

### Claim 34 (depends on 30, 31, 32, 33)

The composition of any of claims 30-33, wherein the first effector moiety comprises a sequence of SEQ ID NO: 19 or 87, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The composition of any of claims 30-34, wherein the first effector moiety comprises a sequence of SEQ ID NO: 129, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The composition of any of claims 30-35, wherein the RNA comprises a nucleotide sequence encoding the first targeting moiety, wherein the nucleotide sequence encoding the first targeting moiety comprises a sequence according to SEQ ID NO: 131 or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The composition of any of claims 30-36, wherein the RNA comprises a nucleotide sequence encoding the first effector moiety, wherein the nucleotide sequence encoding the first effector moiety comprises a sequence according to SEQ ID NO: 132, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35, 36, 37)

The composition of any of claims 30-37, wherein the RNA comprises a nucleotide sequence according to SEQ ID NO: 130, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 39 (depends on 30, 31, 32, 33, 34, 35, 36, 37, 38)

The composition of any of claims 30-38, wherein the RNA further encodes a second expression repressor, wherein the second expression repressor comprises:
a second targeting moiety that binds a second genomic locus, and
a second effector moiety.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the second targeting moiety binds a second genomic locus comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of SEQ ID NO: 77.

### Claim 41 (depends on 39, 40)

The composition of claim 39 or 40, wherein the second targeting moiety comprises a zinc finger domain.

### Claim 42 (depends on 39, 40, 41)

The composition of any of claims 39-41, wherein the second targeting moiety comprises an amino acid sequence according to SEQ ID NO: 7, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 43 (depends on 39, 40, 41, 42)

The composition of any of claims 39-42, wherein the second effector moiety comprises KRAB or a functional variant or fragment thereof.

### Claim 44 (depends on 39, 40, 41, 42, 43)

The composition of any of claims 39-43, wherein the second effector moiety comprises an amino acid sequence according to SEQ ID NO:18, or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 45 (depends on 39, 40, 41, 42, 43, 44)

The composition of any of claims 39-44, wherein the second expression repressor comprises an amino acid sequence according to SEQ ID NO: 24 or a sequence with at least 80, 85, 90, 95, 99, or 100% identity thereto, or having no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 positions of difference thereto.

### Claim 46 (depends on 39, 40, 41, 42, 43, 44, 45)

The composition of any of claims 39-45, wherein the RNA comprises a nucleotide sequence according to SEQ ID NO: 113.

### Claim 47 (depends on 39, 40, 41, 42, 43, 44, 45, 46)

The composition of any of claims 39-46, wherein contacting a plurality of cells with the composition decreases the viability of the plurality of cells.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

A method of treating cancer in a subject in need thereof, the method comprising:
administering to the subject the composition of any of claims 1-47.

### Claim 49 (depends on 48)

The method of claim 48, wherein the cancer is a hepatocellular carcinoma (HCC), Fibrolamellar Hepatocellular Carcinoma (FHCC), Cholangiocarcinoma, Angiosarcoma, or secondary liver cancer.

### Claim 50

A composition comprising:
(1) a nucleic acid (e.g., RNA, e.g., mRNA) encoding an expression repressor, wherein the expression repressor comprises:
(a) a targeting moiety that binds to a MYC promoter or a genomic locus comprising at least 16, 17, 18, 19, or 20 nucleotides of the sequence of any of SEQ ID NOs: 83, 2, 3, 75-86, 97-107, 109, 110, 190-192, or 199-202, and
(b) optionally, an effector moiety,
wherein the expression repressor is capable of decreasing expression of MYC; and
(2) a formulation comprising one or both of:
(i) a first compound having a general structure of formula (IX)
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L1 and L2 are each independently —O(C═O)—, —(C═O)O—, —C(═O)—, —O—, —S(O)x—, —S—S—, —C(═O)S—, —SC(═O)—, —NRaC(═O)—, —C(═O)NRa—, —NRaC(═O)NRa—,
—OC(═O)NRa—, —NRaC(═O)O— or a direct bond;
G′ is C1-C2 alkylene, —(C═O)—, —O(C═O)—, —SC(═O)—, —NRaC(═O)— or a direct bond;
G2 is —C(═O)—, —(C═O)O—, —C(═O)S—, —C(═O)NRa— or a direct bond;
G3 is C1-C6 alkylene;
Ra is H or C1-C12 alkyl;
R1a and R1b are, at each occurrence, independently either: (a) H or C1-C12 alkyl; or (b) R1a is H or C1-C12 alkyl, and R1b together with the carbon atom to which it is bound is taken together with an adjacent R1b and the carbon atom to which it is bound to form a carbon-carbon double bond;
R2a and R2b are, at each occurrence, independently either: (a) H or C1-C12 alkyl; or (b) R2a is H or C1-C12 alkyl, and R2b together with the carbon atom to which it is bound is taken together with an adjacent R2b and the carbon atom to which it is bound to form a carbon-carbon double bond;
R3a and R3b are, at each occurrence, independently either: (a) H or C1-C12 alkyl; or (b) R3a is H or C1-C12 alkyl, and R3b together with the carbon atom to which it is bound is taken together with an adjacent R3b and the carbon atom to which it is bound to form a carbon-carbon double bond;
R4a and R4b are, at each occurrence, independently either: (a) H or C1-C12 alkyl; or (b) R4a is H or C1-C12 alkyl, and R4b together with the carbon atom to which it is bound is taken together with an adjacent R4b and the carbon atom to which it is bound to form a carbon-carbon double bond;
R5 and R6 are each independently H or methyl;
R7 is C4-C20 alkyl;
R8 and R9 are each independently C1-C12 alkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a 5, 6 or 7-membered heterocyclic ring;
a, b, c and d are each independently an integer from 1 to 24; and
x is 0, 1 or 2; and
(ii) a second compound having a general structure of formula (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein R6 and R7 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
y has mean value ranging from 30 to 60.

### Claim 51

A composition comprising:
(1) a nucleic acid (e.g., RNA, e.g., mRNA) encoding an expression repressor, wherein the expression repressor comprises:
(a) a targeting moiety that binds to a MYC promoter or a genomic locus comprising at least 16, 17, 18, 19, or 20 nucleotides of the sequence of any of SEQ ID NOs: 83, 2, 3, 75-86, 97-107, 109, 110, 190-192, or 199-202, and
(b) optionally, an effector moiety,
wherein the expression repressor is capable of decreasing expression of MYC; and
(2) a formulation comprising one or both of:
(i) a first compound having a general structure of formula (XI)
or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein:
R1 is optionally substituted C1-C24 alkyl or optionally substituted C2-C24 alkenyl;
R2 and R3 are each independently optionally substituted C1-C36 alkyl;
R4 and R are each independently optionally substituted C1-C6 alkyl, or R4 and R join, along with the N to which they are attached, to form a heterocyclyl or heteroaryl;
L1, L2, and L3 are each independently optionally substituted C1-C15 alkylene;
G1 is a direct bond, —(CH2)nO(C═O)—, —(CH2)n(C═O)O—, or —(C═O)—;
G2 and G3 are each independently —(C═O)O— or —O(C═O)—; and
n is an integer greater than 0; and
(ii) a second compound having a general structure of formula (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof,
wherein R6 and R7 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
y has mean value ranging from 30 to 60.
